New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
09:36 EDTAAPL, ABX, TWTR, GILD, LVSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD ABX LVS TWTR
News For AAPL;GILD;ABX;LVS;TWTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>
September 21, 2015
14:40 EDTAAPLiPath S&P 500 VIX Short-Term Futures down 90c to 23.79
Option volume leaders: AAPL NFLX BAC FB BABA DOW TSLA
14:04 EDTGILDClinton vow to end drug price gouging sinks biotechs
Biotech stocks have declined across the board in afternoon trading following a tweet by Presidential candidate Hillary Clinton criticizing the "outrageous" prices of specialty drugs. TURING STEPS UP PRICING: Clinton's tweet directly referenced Turing Pharmaceuticals' Daraprim treatment for toxoplasmosis, which recently had its price hiked from just $13.50 per pill to $750 after the privately-held company acquired the drug from Impax Laboratories (IPXL). Importantly, Daraprim was first approved by the FDA in 1953 and its patents have long since expired. No generic versions of the drug currently exist, perhaps in part due to Turing executive chairman Martin Shkreli's strategy of tightly controlling distribution, according to a New York Post article on the issue. In a Bloomberg TV interview this morning, Shkreli claimed that the drug remains underpriced compared to what he called its peers in the rare disease space. However, note that a World Health Organization analysis from 2013 reported that over 190,000 cases of toxoplasmosis occur globally every year and Daraprim continues to be listed on the organization's list of essential medicines for a basic health-care system. INDUSTRY CRITICISM: Turing's Daraprim pricing prompted a response from the Infectious Diseases Society of America and the HIV Medicine Association, which criticized the "unjustifiable" new cost of the drug and urged a "rational" pricing strategy. The news surrounding Daraprim also comes on the heels of Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Hospira (HSP), in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. REPUBLICAN CONGRESS: In a research note released this afternoon, RBC Capital analyst Michael Yee reminded investors that Republicans still control Congress, offering a sobering reminder that campaign trail promises often fall by the wayside once the candidate steps into office. Yee explained that, though drug pricing debates during next year's election will probably generate headline risk for the biotech space, the Republican-controlled Congress is unlikely to sign into law any material changes on the issue. BIOTECH STOCK ACTION: Hillary Clinton's promise to "lay out a plan" tomorrow to tackle "price gouging" in the specialty drug market sent numerous biotech stocks plunging. Aerie Pharmaceuticals (AERI) has crashed 12.6% at time of writing, while Retrophin (RTRX), Ultragenyx (RARE), and PTC Therapeutics (PTCT) are down 14.7%, 13.4%, and 11%, respectively. Biotech giants AbbVie (ABBV), Gilead (GILD), Bristol-Myers Squibb (BMY) and Biogen (BIIB) have also slipped in intraday trading, while the NASDAQ Biotechnology index is down roughly 4%.
13:52 EDTAAPLTesla options active on Apple accelerates electric-car plan report
Tesla (TSLA) September weekly 255 and 260 puts are active on total put volume of 48K contracts (49K calls) following the WSJ's report Apple (AAPL) accelerates electric-car plan, targets shipment in 2019. September weekly put option implied volatility is at 47, October is at 46; compared to its 52-week range of 29 to 62. Active options volume suggests traders taking positions for large price movement.
13:47 EDTAAPLApple accelerates electric car plan, WSJ reports
Subscribe for More Information
13:43 EDTAAPLApple accelerates electric-car plan, targets shipment in 2019, WSJ reports
Shares of electric car maker Tesla (TSLA) have moved into negative ground following the Journal's report. Reference Link
13:17 EDTGILDRBC reminds biotech investors that Republicans still control Congress
RBC Capital analyst Michael Yee notes that biotech indices are under pressure after Hillary Clinton tweeted about an upcoming plan to fight specialty drug pricing. The news follows a Wall Street Journal story about a private company dramatically increasing the price of their drug and another confirmed progressive multifocal leukoencephalopathy case for Biogen (BIIB), Yee tells investors in an intraday research note. Next year's election is likely to turn up the noise around drug pricing, creating headline risk for the biotech space, the analyst cautions. However, he reminds investors that Republicans control Congress, making it unlikely that "anything material" will get signed into law. Biotech names moving lower in today's trading include Biogen, AbbVie (ABBV), Gilead (GILD), Alkermes (ALKS), BioMarin (BMRN), Amicus (FOLD) and PTC Therapeutics (PTCT).
11:51 EDTTWTRStocks with call strike movement; TWTR NFLX
Subscribe for More Information
10:49 EDTAAPLGoPro falls after Barron's predicts 'dramatic' drop in share price
GoPro (GPRO) shares fell in morning trading after an article from Barron's argued that the company's share price may drop to as low as $25. WHAT'S NEW: Alexander Eule argued in a Barron's article that GoPro's stock price may see a "dramatic" slip of as much as 30% to $25 due to significant competitive pressure from Apple (AAPL), Sony (SNE) and others. Eule noted that the company's shares have crashed to a recent $35 after peaking at $98 in October 2014 and even called the mostly bullish analyst views on the camera maker's stock "wishful thinking." Additionally, Eule called the company's cameras a "one-product wonder" and compares them to BlackBerry (BBRY) smartphones and Palm digital organizers, which previously dominated their respective markets. The article adds that there is risk in being overly bearish on the company, since the "impressive" brand might become an acquisition target. WHAT'S NOTABLE: Last Wednesday, Citi analyst Jeremy David said that GoPro chief financial officer Jack Lazar confirmed at the bank's Global Tech Conference the week before that the Hero4 Session camera has been off to a slow start since its launch on July 12. David said that the recent selloff in the company's shares has been motivated by investor concerns about the Session. At the time, Citi cut its third quarter fiscal 2015 estimate for the company to $425M from $438M and fourth quarter estimate to $560M from $737M, $148M below consensus estimate at the time of $708M. David also said he was reducing estimates for the second half of fiscal 2015 and first quarter of fiscal 2016 as a result of downside from the Hero4 Session, but left estimates after 1Q16 unchanged, saying the long-term fundamentals of the company are "intact." The analyst added that his firm was "humbled" by the recent move in share price and acknowledged that GoPro is the "quintessential product cycle stock," though he said he remains bullish on the long-term prospects of the camera maker and reiterated a $90 price target. David argued that GoPro missing Q3 estimates and guiding below the consensus for Q4 is largely priced in. Separately, The Wall Street Journal said on September 13 that shares of GoPro were starting to look like a bargain after dropping 50% in a month. The company had a difficult time selling its Hero4 Session camera in July in the face of competition from older GoPro models, the publication added. PRICE ACTION: In morning trading, GoPro shares are down 5.15% to $33.34. OTHERS TO WATCH: Ambarella (AMBA), which supplies chips to GoPro, is down 3.7% to $68.81.
09:40 EDTAAPL, TWTRActive equity options trading on open
Active equity options trading on open: AAPL BAC ESV BABA FB NFLX TSLA TWTR GE GPRO JPM ONVO MU
08:34 EDTGILDGilead reports results from four international Phase 3 ASTRAL studies
Subscribe for More Information
08:31 EDTAAPLApple says iPhone 6s, iPhone 6s Plus to arrive on Friday, September 25
Apple announced iPhone 6s and iPhone 6s Plus will be available at 8:00 a.m. local time on Friday, September 25 at Apple's retail stores. Stores will have the new iPhones available for walk-in customers who are encouraged to arrive early. Both models will also be available on Friday from AT&T, Sprint, T-Mobile, Verizon Wireless, additional carriers and select Apple Authorized Resellers. Apple also announced the fastest iOS adoption ever, with more than 50 percent of devices already using iOS 9. Apple says "iPhone 6s and iPhone 6s Plus bring a powerful new dimension to iPhone's revolutionary Multi-Touch(TM) interface with 3D Touch, which senses how deeply you press the display, letting you do essential things more quickly and simply. The new iPhones introduce Live Photos, which bring still images to life, transforming instants frozen in time into unforgettable living memories. Live Photos, 3D Touch, 12-megapixel iSight camera, 5-megapixel FaceTime HD camera with Retina Flash and more are powered by the Apple-designed A9 chip, the most advanced chip ever in a smartphone, delivering faster performance and great battery life. iPhone 6s and iPhone 6s Plus are designed with the strongest glass on any smartphone and 7000 series aluminum, the same alloy used in the aerospace industry, in gorgeous metallic finishes that now include rose gold."
08:22 EDTAAPLApple survey suggests strong iPhone demand, says Baird
Subscribe for More Information
07:43 EDTAAPLApple surveys indicate iPhone increasing high-end share, says Canaccord
Subscribe for More Information
06:34 EDTAAPLSamsung may be planning leasing program for Galaxy phones, Forbes reports
Samsung (SSNLF) is rumored to be planning to launch a leasing program for its Galaxy phones in the U.S., similar to the program Apple (AAPL) recently announced, Forbes reports, citing an industry executive with knowledge of Samsung's plans. According to the source, Samsung could launch the leasing program in the next few months. Apple's iPhone Upgrade Program encourages consumers to buy iPhones directly from the Apple Store instead of going through carriers, the publication notes. Publicly traded wireless carriers include AT&T (T), Verizon (VZ), Sprint (S) and T-Mobile US (TMUS). Reference Link
06:24 EDTAAPLFoxconn seeks to acquire Sharp's LCD business, Nikkei reports
Taiwan's Hon Hai Precision Industry, better known as Foxconn (HNHPF) has offered to buy Sharp's (SHCAY) struggling LCD business and plans to seek funding from Apple (AAPL), a key Sharp customer, The Nikkei reports. According to the report, Foxconn would take a majority stake in a LCD company spun off by Sharp, with Apple also making an investment. Reference Link
06:21 EDTABXBarrick Gold seeing 'strong' interest in gold assets, Reuters reports
Subscribe for More Information
06:07 EDTAAPLApple hit by rare malware in China, Financial Times reports
Subscribe for More Information
06:07 EDTAAPLApple meets with regulators to discuss self-driving cars, Financial Times says
Subscribe for More Information
September 20, 2015
14:46 EDTAAPLCompany split may not end troubles at Hewlett-Packard, Barron's says
Subscribe for More Information
12:49 EDTAAPLGoPro shares could fall another 30% to $25, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use